Type Two Diabetes Drug Bydureon Approved by FDA

A new diabetes drug has made it to the market after a long delay by the Food and Drug Administration (FDA). The FDA approved Amylin Pharmacuetical’s drug Bydureon just a few days ago. Bydureon is a once a week injection medication created to improve glycemic control in adults with type 2 diabetes in multiple settings. In 2010, the FDA rejected the drugs approval twice, requesting more studies be done, but Bydureon has finally been approved. Amylin is hoping with the new drugs convenient once a week use, it will gain an advantage over competitors. The company plans to sell the new diabetes drug in both the U.S. and Europe, they are expected to hit $1 billion in annual sales. (read full article)


According to the American Diabetes Association, type 2 diabetes is the most common form of diabetes; it affects millions of Americans every day. With type 2 diabetes, the body does not produce enough insulin or the cells ignore the insulin, and insulin is necessary for the body to be able to use glucose for energy. Untreated patients with type 2 diabetes may experience constant fatigue, weight loss, blurred vision, increased thirst and several other serious side effects. Over the past few years, pharmaceutical companies have tried to find alternative options for diabetic patients when it comes to injections or oral medication and as of now, Amylin’s Bydureon is the only type two diabetic medication for adults with a once a week dose. The company has tested the drug for any side effects and has clearly posted all possibilities on the label.


If you or a loved one have ever taken a prescription drug and felt you were not properly warned about the side effects or the drug did not work as you were told, don’t hesitate to contact an attorney. At Borchardt Law Firm we want to make sure the medicine patients are taking is safe. We have dealt with several defective prescription drug cases and feel the work we do will protect future generations of Texans. Feel free to give us a call.

Toll Free: 866.832.9300
Phone: 817.332.9300
Fax: 817.332.93011300
South University Drive, Suite 500
Fort Worth, Texas 76102